Eden Biodesign Confirms Research Triangle Park Facility
News Jun 26, 2008
Eden Biodesign Ltd. has confirmed its expansion plans for Eden Biodesign, Inc., the Group’s US subsidiary, with the announcement of a facility in the Research Triangle Park, North Carolina.
Building on the strong track record and recent growth of its UK cGMP facility, Eden Biodesign, Inc., will offer a range of cell line/strain development and early process development services.
Eden Biodesign provides services in support of all major biopharmaceutical production technologies (mammalian, microbial and viral) and offers a “toolbox” of expression technologies, some via collaboration with partner companies.
“The selection of North Carolina’s world-renowned Research Triangle Park signifies the strategic importance of the North American market to Eden Biodesign”, said Dr. Crawford Brown, Chief Executive Officer, Eden Biodesign. “By establishing a subsidiary in the United States we are making it easier for clients to access Eden’s proven expertise and inspected cGMP manufacturing facilities and confirming Eden’s position as a recognized global player in the contract biopharmaceutical manufacturing services market”.
Eden Biodesign is further cementing its commitment to the North American market with the recent appointment of Michael Faughnan as Business Development Director, who will be supporting the Company’s expansion into the North American market from Southern California. The Company is actively developing technology and marketing collaborations with industry leaders throughout North America.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE